» Articles » PMID: 36497907

Human-Based New Approach Methodologies in Developmental Toxicity Testing: A Step Ahead from the State of the Art with a Feto-Placental Organ-on-Chip Platform

Overview
Publisher MDPI
Date 2022 Dec 11
PMID 36497907
Authors
Affiliations
Soon will be listed here.
Abstract

Developmental toxicity testing urgently requires the implementation of human-relevant new approach methodologies (NAMs) that better recapitulate the peculiar nature of human physiology during pregnancy, especially the placenta and the maternal/fetal interface, which represent a key stage for human lifelong health. Fit-for-purpose NAMs for the placental-fetal interface are desirable to improve the biological knowledge of environmental exposure at the molecular level and to reduce the high cost, time and ethical impact of animal studies. This article reviews the state of the art on the available in vitro (placental, fetal and amniotic cell-based systems) and in silico NAMs of human relevance for developmental toxicity testing purposes; in addition, we considered available Adverse Outcome Pathways related to developmental toxicity. The OECD TG 414 for the identification and assessment of deleterious effects of prenatal exposure to chemicals on developing organisms will be discussed to delineate the regulatory context and to better debate what is missing and needed in the context of the Developmental Origins of Health and Disease hypothesis to significantly improve this sector. Starting from this analysis, the development of a novel human feto-placental organ-on-chip platform will be introduced as an innovative future alternative tool for developmental toxicity testing, considering possible implementation and validation strategies to overcome the limitation of the current animal studies and NAMs available in regulatory toxicology and in the biomedical field.

Citing Articles

Digital twin-enhanced three-organ microphysiological system for studying drug pharmacokinetics in pregnant women.

Graf K, Murrieta-Coxca J, Vogt T, Besser S, Geilen D, Kaden T Front Pharmacol. 2025; 16:1528748.

PMID: 40034823 PMC: 11873563. DOI: 10.3389/fphar.2025.1528748.


Standardization and optimization of the hiPSC-based PluriLum assay for detection of embryonic and developmental toxicants.

Treschow A, Vinggaard A, Valente M Arch Toxicol. 2024; 98(12):4107-4116.

PMID: 39365317 PMC: 11496362. DOI: 10.1007/s00204-024-03870-8.


Multi-cellular engineered living systems to assess reproductive toxicology.

Lopez I, Truskey G Reprod Toxicol. 2024; 127:108609.

PMID: 38759876 PMC: 11179964. DOI: 10.1016/j.reprotox.2024.108609.


Investigating the applicability domain of the hiPSC-based PluriLum assay: an embryotoxicity assessment of chemicals and drugs.

Treschow A, Valente M, Lauschke K, Holst B, Andersen A, Vinggaard A Arch Toxicol. 2024; 98(4):1209-1224.

PMID: 38311648 PMC: 10944425. DOI: 10.1007/s00204-023-03675-1.


Review on new approach methods to gain insight into the feto-maternal interface physiology.

Menon R, Muglia L, Levin L Front Med (Lausanne). 2023; 10:1304002.

PMID: 38098843 PMC: 10720461. DOI: 10.3389/fmed.2023.1304002.

References
1.
Busquet F, Kleensang A, Rovida C, Herrmann K, Leist M, Hartung T . New European Union statistics on laboratory animal use - what really counts!. ALTEX. 2020; 37(2):167-186. DOI: 10.14573/altex.2003241. View

2.
Murphy S, Atala A . Amniotic fluid and placental membranes: unexpected sources of highly multipotent cells. Semin Reprod Med. 2013; 31(1):62-8. DOI: 10.1055/s-0032-1331799. View

3.
Richardson L, Gnecco J, Ding T, Osteen K, Rogers L, Aronoff D . Fetal Membrane Organ-On-Chip: An Innovative Approach to Study Cellular Interactions. Reprod Sci. 2020; 27(8):1562-1569. DOI: 10.1007/s43032-020-00184-9. View

4.
Petetta F, Ciccocioppo R . Public perception of laboratory animal testing: Historical, philosophical, and ethical view. Addict Biol. 2020; 26(6):e12991. PMC: 9252265. DOI: 10.1111/adb.12991. View

5.
Melau C, Lundgaard Riis M, Nielsen J, Perlman S, Lundvall L, Langhoff Thuesen L . The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions. BMC Med. 2021; 19(1):204. PMC: 8425147. DOI: 10.1186/s12916-021-02080-8. View